<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">8359</article-id><article-id pub-id-type="doi">10.15690/vramn8359</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CARDIOLOGY AND CARDIOVASCULAR SURGERY: CURRENT ISSUES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ВОПРОСЫ КАРДИОЛОГИИ И СЕРДЕЧНО-СОСУДИСТОЙ ХИРУРГИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Cardiovascular and oncological diseases — focus on modifiable risk factors and modern pathogenetic aspects</article-title><trans-title-group xml:lang="ru"><trans-title>Сердечно-сосудистые и онкологические заболевания — фокус на модифицируемых факторах риска и современные патогенетические аспекты</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7016-7541</contrib-id><contrib-id contrib-id-type="spin">2856-3356</contrib-id><name-alternatives><name xml:lang="en"><surname>Buziashvili</surname><given-names>Jurij I.</given-names></name><name xml:lang="ru"><surname>Бузиашвили</surname><given-names>Юрий Иосифович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Academician of the RAS</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, академик РАН</p></bio><email>buziashvili@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5229-8203</contrib-id><contrib-id contrib-id-type="spin">9622-7106</contrib-id><name-alternatives><name xml:lang="en"><surname>Stilidi</surname><given-names>Ivan S.</given-names></name><name xml:lang="ru"><surname>Стилиди</surname><given-names>Иван Сократович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Academician of the RAS</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, академик РАН</p></bio><email>director@ronc.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5670-167X</contrib-id><contrib-id contrib-id-type="spin">2827-1317</contrib-id><name-alternatives><name xml:lang="en"><surname>Mackeplishvili</surname><given-names>Simon T.</given-names></name><name xml:lang="ru"><surname>Мацкеплишвили</surname><given-names>Симон Теймуразович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, associate member RAS</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, чл.-корр. РАН</p></bio><email>simonmats@yahoo.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5422-2069</contrib-id><contrib-id contrib-id-type="spin">8108-3978</contrib-id><name-alternatives><name xml:lang="en"><surname>Asymbekova</surname><given-names>El’mira U.</given-names></name><name xml:lang="ru"><surname>Асымбекова</surname><given-names>Эльмира Уметовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>д.м.н.</p></bio><email>elmasym@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1751-4924</contrib-id><contrib-id contrib-id-type="spin">3662-8775</contrib-id><name-alternatives><name xml:lang="en"><surname>Tugeeva</surname><given-names>Elvina F.</given-names></name><name xml:lang="ru"><surname>Тугеева</surname><given-names>Эльвина Фаатовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>д.м.н.</p></bio><email>Elvina.tugeeva@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7728-9533</contrib-id><contrib-id contrib-id-type="spin">2483-6309</contrib-id><name-alternatives><name xml:lang="en"><surname>Artamonova</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Артамонова</surname><given-names>Елена Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>д.м.н.</p></bio><email>artamonovae@mail.ru</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1675-4216</contrib-id><name-alternatives><name xml:lang="en"><surname>Akildzhonov</surname><given-names>Firdavsdzhon R.</given-names></name><name xml:lang="ru"><surname>Акилджонов</surname><given-names>Фирдавсджон Рустамджонович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>firdavs96_tths@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7800-9078</contrib-id><name-alternatives><name xml:lang="en"><surname>Rakhmanzhanov</surname><given-names>Alier A.</given-names></name><name xml:lang="ru"><surname>Рахманжанов</surname><given-names>Алиер Алишерович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alier.raxmanzhanov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6252-0322</contrib-id><contrib-id contrib-id-type="spin">9334-5672</contrib-id><name-alternatives><name xml:lang="en"><surname>Golukhova</surname><given-names>Elena Z.</given-names></name><name xml:lang="ru"><surname>Голухова</surname><given-names>Елена Зеликовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Academician of the RAS</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, академик РАН</p></bio><email>egoluhova@bakulev.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">A.N. Bakulev National Medical Research Center of Cardiovascular Surgery</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">Российский национальный исследовательский медицинский университет им. Н.И. Пирогова</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Moscow Regional Research and Clinical Institute (MONIKI)</institution></aff><aff><institution xml:lang="ru">Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-05-24" publication-format="electronic"><day>24</day><month>05</month><year>2023</year></pub-date><volume>78</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>132</fpage><lpage>140</lpage><history><date date-type="received" iso-8601-date="2023-03-28"><day>28</day><month>03</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-04-28"><day>28</day><month>04</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Издательство "Педиатръ"</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2024-05-24"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnikramn.spr-journal.ru/jour/about/submissions</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/8359">https://vestnikramn.spr-journal.ru/jour/article/view/8359</self-uri><abstract xml:lang="en"><p><italic>Currently, in modern medicine, there has been a sharp increase in interest in the combined pathology of cardiovascular diseases (CVD) with other nosologies, such as diabetes mellitus, chronic kidney disease, and oncopathology. Over the past decades, there have been large positive shifts in survival in this cohort of patients. An integral specialty of cardio-oncology is rapidly developing, which is aimed at improving the results of treatment of oncological patients. Due to increased life expectancy and improved long-term prognosis in cancer patients, in particular, the adverse effects of anticancer therapy have attracted great attention from researchers. The causal relationship between cancer and CVD can be partly explained by a common profile of modifiable and non-modifiable risk factors. There is also strong evidence that a systemic inflammatory response is a common pathophysiological determinant of cancer and CVD. General risk factors for development and progression, as well as pathogenetic mechanisms, contribute to high mortality rates. Increasing knowledge of pathophysiological mechanisms will help elucidate the general molecular aspects of carcinogenesis and cardiovascular disease. This review presents general modifiable risk factors and current pathogenetic aspects of cardiovascular and oncological diseases.</italic></p></abstract><trans-abstract xml:lang="ru"><p><italic>В настоящее время в современной медицине резко вырос интерес к сочетанной патологии сердечно-сосудистых заболеваний (ССЗ) с другими нозологиями, такими как сахарный диабет, хроническая болезнь почек и онкопатология. За последние десятилетия произошли большие положительные сдвиги в выживаемости у данной когорты пациентов. Стремительно развивается интегральная специальность «кардиоонкология», которая направлена на улучшение результатов лечения онкологических пациентов. В связи с увеличением продолжительности жизни и улучшением отдаленного прогноза у онкологических пациентов, в частности, неблагоприятные эффекты противоопухолевой терапии привлекли огромное внимание исследователей. Причинно-следственная связь между онкологическими болезнями и ССЗ может быть частично объяснена общим профилем модифицируемых и немодифицируемых факторов риска. Также существуют убедительные доказательства, что системная воспалительная реакция является общей патофизиологической детерминантой онкологических болезней и ССЗ. Общие факторы риска развития и прогрессирования, а также патогенетические механизмы способствуют высоким цифрам летальности. Расширение знаний о патофизиологических механизмах поможет прояснить общие молекулярные аспекты канцерогенеза и ССЗ. В настоящем обзоре представлены общие модифицируемые факторы риска и современные патогенетические аспекты ССЗ и онкологических заболеваний.</italic></p></trans-abstract><kwd-group xml:lang="en"><kwd>risk factors</kwd><kwd>сardiooncology</kwd><kwd>C-reactive protein</kwd><kwd>inflammation</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>факторы риска</kwd><kwd>кардиоонкология</kwd><kwd>С-реактивный белок</kwd><kwd>воспаление</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Sturgeon K, Deng L, Bluethmann S. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889–3897. doi: https://doi.org/10.1093/eurheartj/ehz766</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Ngo D, Williams T, Horder S. Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab. J Clin Med. 2020;9(8):2664. doi: https://doi.org/10.3390/jcm9082664</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Al-Kindi S, Oliveira G. Prevalence of Preexisting Cardiovascular Disease in Patients with Different Types of Cancer: The Unmet Need for Onco-Cardiology. Mayo Clin Proc. 2016;91(1):81–83. doi: https://doi.org/10.1016/j.mayocp.2015.09.009</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Han X, Zhou Y, Liu W. Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. NPJ Precis Oncol. 2017;1(1):31. doi: https://doi.org/10.1038/s41698-017-0034-x</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Sung H, Ferlay J, Siegel R. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi: https://doi.org/10.3322/caac.21660</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Thun M, DeLancey J, Center M, et al. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010;31(1):100–110. doi: https://doi.org/10.1093/carcin/bgp263</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Nguyen P, Saito E, Katanoda K. Long-Term Projections of Cancer Incidence and Mortality in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020–2054: An Empirical Validation Approach. Cancers (Basel). 2022;14(24):6076. doi: https://doi.org/10.3390/cancers14246076</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Васюк Ю.А., Гендлин Г.Е., Емелина Е.И. Согласованное мнение российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии // Российский кардиологический журнал. — 2021. — Т. 26. — № 9. — 4703. doi: https://doi.org/10.15829/1560-4071-2021-4703 [Vasyuk Yu, Gendlin G, Emelina EI. Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology. 2021;26(9):4703. (In Russ.)] doi: https://doi.org/10.15829/1560-4071-2021-4703</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lyon A, López-Fernández T, Couch L. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–4361. doi: https://doi.org/10.1093/eurheartj/ehac244</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Khanna A, Pequeno P, Gupta S. Increased Risk of All Cardiovascular Disease Subtypes Among Childhood Cancer Survivors: Population-Based Matched Cohort Study. Circulation. 2019;140(12):1041–1043. doi: https://doi.org/10.1161/CIRCULATIONAHA.119.041403</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Clèries R, Ameijide A, Buxó M. Ten-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain. Int J Environ Res Public Health. 2022;20(1):405. doi: https://doi.org/10.3390/ijerph20010405</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Zamorano J, Gottfridsson C, Asteggiano R. The cancer patient and cardiology. Eur J Heart Fail. 2020;22(12):2290–2309. doi: https://doi.org/10.1002/ejhf.1985</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Quoc Lam B, Shrivastava S, Shrivastava A, et al. The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives. J Cell Mol Med. 2020;24(14):7706–7716. doi: https://doi.org/10.1111/jcmm.15413</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Krupa-Kotara K, Dakowska D. Impact of obesity on risk of cancer. Cent Eur J Public Health. 2021;29(1):38–44. doi: https://doi.org/10.21101/cejph.a5913</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Du X, Hidayat K, Shi B. Abdominal obesity and gastroesophageal cancer risk: systematic review and meta-analysis of prospective studies. Biosci Rep. 2017;37(3):BSR20160474. doi: https://doi.org/10.1042/BSR20160474</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Shang L, Hattori M, Fleming G. Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Res. 2021;23(1):18. doi: https://doi.org/10.1186/s13058-021-01397-9</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Tangvarasittichai S, Pongthaisong S, Tangvarasittichai O. Tumor Necrosis Factor-Α, Interleukin-6, C-Reactive Protein Levels and Insulin Resistance Associated with Type 2 Diabetes in Abdominal Obesity Women. Indian J Clin Biochem. 2016;31(1):68–74. doi: https://doi.org/10.1007/s12291-015-0514-0</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Poetsch M, Strano A, Guan K. Role of Leptin in Cardiovascular Diseases. Front Endocrinol (Lausanne). 2020;11:354. doi: https://doi.org/10.3389/fendo.2020.00354</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Ellulu M, Patimah I, Khaza’ai H, et al. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851–863. doi: https://doi.org/10.5114/aoms.2016.58928</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Xu J, Lin H, Wu G, et al. IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma. Front Oncol. 2021;11:760971. doi: https://doi.org/10.3389/fonc.2021.760971</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Eketunde A. Diabetes as a Risk Factor for Breast Cancer. Cureus. 2020;12(5):e8010. doi: https://doi.org/10.7759/cureus.8010</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Xu C, Zhu H, Zhu Y. Diabetes and cancer: Associations, mechanisms, and implications for medical practice. World J Diabetes. 2014;5(3):372–380. doi: https://doi.org/10.4239/wjd.v5.i3.372</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Hormati A, Hajrezaei Z, Jazi K, et al. Gastrointestinal and Pancratohepatobiliary Cancers: A Comprehensive Review on Epidemiology and Risk Factors Worldwide. Middle East J Dig Dis. 2022;14(1):5–23. doi: https://doi.org/10.34172/mejdd.2022.251</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Gu L, Ma G, Li C, et al. New insights into the prognosis of intraocular malignancy: Interventions for association mechanisms between cancer and diabetes. Front Oncol. 2022;12:958170. doi: https://doi.org/10.3389/fonc.2022.958170</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Travis R, Appleby P., Martin R. A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Res. 2016;76(8):2288–2300. doi: https://doi.org/10.1158/0008-5472.CAN-15-1551</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Nounu A, Kar S, Relton C, Richmond R. Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study. Breast Cancer Res. 2022;24(1):66. doi: https://doi.org/10.1186/s13058-022-01553-9</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Ba Z, Xiao Y, He M. Risk Factors for the Comorbidity of Hypertension and Renal Cell Carcinoma in the Cardio-Oncologic Era and Treatment for Tumor-Induced Hypertension. Front Cardiovasc Med. 2022;9:810262. doi: https://doi.org/10.3389/fcvm.2022.810262</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>El Hadri K, Smith R, Duplus E, El Amri C. Inflammation, Oxidative Stress, Senescence in Atherosclerosis: Thioredoxine-1 as an Emerging Therapeutic Target. Int J Mol Sci. 2021;23(1):77. doi: https://doi.org/10.3390/ijms23010077</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Angel-Korman A, Rapoport V, Leiba A. The Relationship between Hypertension and Cancer. Isr Med Assoc J. 2022;24(3):165–169.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Grossman E, Messerli F, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med. 2002;112(6):479–486. doi: https://doi.org/10.1016/s0002-9343(02)01049-5</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Skorupan N, Palestino Dominguez M, Ricci S, Alewine C. Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2022;14(17):4209. doi: https://doi.org/10.3390/cancers14174209</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Cedó L, Reddy S, Mato E, et al. HDL and LDL: Potential New Players in Breast Cancer Development. J Clin Med. 2019;8(6):853. doi: https://doi.org/10.3390/jcm8060853</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Larsson S, Carter P, Kar S. Smoking, alcohol consumption, and cancer: A mendelian randomisation study in UK Biobank and international genetic consortia participants. PLoS Med. 2020;17(7):e1003178. doi: https://doi.org/10.1371/journal.pmed.1003178</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Greten F, Grivennikov S. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27–41. doi: https://doi.org/10.1016/j.immuni.2019.06.025</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Perillo B, Di Donato M, Pezone A. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52(2):192–203. doi: https://doi.org/10.1038/s12276-020-0384-2</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Ridker P. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res. 2016;118(1):145–156. doi: https://doi.org/10.1161/CIRCRESAHA.115.306656</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Johnson D, O’Keefe R, Grandis J. Targeting the IL-6/JAK/STAT3 signaling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234–248. doi: https://doi.org/10.1038/nrclinonc.2018.8</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Ya G, Ren W, Qin R, et al. Role of myeloid-derived suppressor cells in the formation of pre-metastatic niche. Front Oncol. 2022;12:975261. doi: https://doi.org/10.3389/fonc.2022.975261</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Crossman D, Rothman A. Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS). J Thorac Dis. 2018;10(Suppl 26):S3084–S3087. doi: https://doi.org/10.21037/jtd.2018.07.50</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Lust J, Lacy M, Zeldenrust S. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84(2):114–122. doi: https://doi.org/10.4065/84.2.114</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Nguyen M, Bui K, Scholta T. Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma. J Gastroenterol Hepatol. 2021;36(5):1334–1345. doi: https://doi.org/10.1111/jgh.15307</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Kuo M, Chang S, Hsieh M. Colchicine Significantly Reduces Incident Cancer in Gout Male Patients: A 12-Year Cohort Study. Medicine (Baltimore). 2015;94(50):e1570. doi: https://doi.org/10.1097/MD.0000000000001570</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Carreira R, Lee P, Gottlieb R. Mitochondrial therapeutics for cardioprotection. Curr Pharm Des. 2011;17(20):2017–2035. doi: https://doi.org/10.2174/138161211796904777</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Roth K, Mambetsariev I, Kulkarni P, Salgia R. The Mitochondrion as an Emerging Therapeutic Target in Cancer. Trends Mol Med. 2020;26(1):119–134. doi: https://doi.org/10.1016/j.molmed.2019.06.009</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Bowman R, Busque L, Levine R. Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. Cell Stem Cell. 2018;22(2):157–170. doi: https://doi.org/10.1016/j.stem.2018.01.011</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Poller W, Nahrendorf M, Swirski F. Hematopoiesis and Cardiovascular Disease. Circ Res. 2020;126(8):1061–1085. doi: https://doi.org/10.1161/CIRCRESAHA.120.315895</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Libby P, Sidlow R, Lin A. Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74(4):567–577. doi: https://doi.org/10.1016/j.jacc.2019.06.007</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Jaiswal S, Natarajan P, Silver A. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377(2):111–121. doi: https://doi.org/10.1056/NEJMoa1701719</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Senguttuvan N, Subramanian V, Venkatesan V, et al. Clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular diseases-an updated systematic review. J Genet Eng Biotechnol. 2021;19(1):105. doi: https://doi.org/10.1186/s43141-021-00205-3</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Pascual-Figal D, Bayes-Genis A, Díez-Díez M. Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2021;77(14):1747–1759. doi: https://doi.org/10.1016/j.jacc.2021.02.028</mixed-citation></ref></ref-list></back></article>
